引用

腹泻是全世界5岁以下儿童最常见的感染疾病。尽管如此，治疗感染性腹泻的疫苗只有少数，许多可用的疫苗是少量和零星的。发展和广泛实施疫苗接种的主要障碍包括生产、分发和交付的容易程度和成本。在这里，我们提出了一种新颖的、可定制的和自组装的疫苗平台，利用霍乱弧菌生物膜基质进行抗原呈递。我们利用这项技术创造了一种概念验证的全细胞减毒活疫苗，这种疫苗是由分泌的蛋白抗原与细胞表面自发结合而增强的。将这种减毒活疫苗舌下注射给小鼠，可对病毒产生保护作用。挑战并诱导产生抗原特异性粪便IgA。这里介绍的平台使抗原增强疫苗的开发成为可能，这些疫苗易于生产和交付，解决了针对腹泻疾病的疫苗接种的许多障碍。这也可以作为开发针对其他粘膜感染的广泛保护性生物膜疫苗的范例。重要的是，腹泻是全世界儿童最常见的传染病。在资源贫乏的环境中，这些感染与认知迟缓、发育迟缓和过早死亡有关。 With the development of efficacious, affordable, and easily administered vaccines, such infections could be prevented. While a major focus of biofilm research has been their elimination, here we harness the bacterial biofilm to create a customizable platform for cost-effective, whole cell mucosal vaccines that self-incorporate secreted protein antigens. We use this platform to develop a sublingually administered, live-attenuated prototype vaccine based onVibrio cholerae.This serves not only as a proof-of-concept for a multivalent vaccine against common bacterial enteric pathogens but also as a paradigm for vaccines utilizing other bacterial biofilms to target mucosal infections. Copyright 2018 American Society for Microbiology.